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ABSTRACT: The gold standard of molecular pathogen detection is the quantitative polymerase
chain reaction (qPCR). Modern qPCR instruments are capable of detecting 4−6 analytes in a
single sample: one per optical detection channel. However, many clinical applications require
multiplexing beyond this traditional single-well capacity, including the task of simultaneously
testing for SARS-CoV-2 and other respiratory pathogens. This can be addressed by dividing a
sample across multiple wells, or using technologies such as genomic sequencing and spatial arrays,
but at the expense of significantly higher cost and lower throughput compared with single-well
qPCR. These trade-offs represent unacceptable compromises in high-throughput screening
scenarios such as SARS-CoV-2 testing. We demonstrate a novel method of detecting up to 20
targets per well with standard qPCR instrumentation: high-definition PCR (HDPCR). HDPCR
combines TaqMan chemistry and familiar workflows with robust encoding to enable far higher
levels of multiplexing on a traditional qPCR system without an increase in cost or reduction in
throughput. We utilize HDPCR with a custom 20-Plex assay, an 8-Plex assay using unmodified
predesigned single-plex assays from Integrated DNA Technologies and a 9-Plex pathogen panel
inclusive of SARS-CoV-2 and other common respiratory viruses. All three assays were successful when tested on a variety of samples,
with overall sample accuracies of 98.8, 98.3, and 100%, respectively. The HDPCR technology enables the large install base of qPCR
instrumentation to perform mid-density multiplex diagnostics without modification to instrumentation or workflow, meeting the
urgent need for increased diagnostic yield at an affordable price without sacrificing assay performance.
■ INTRODUCTION
Single-target quantitative polymerase chain reaction (qPCR) is
the gold standard for molecular pathogen detection. However,
testing for only a single target per qPCR leads to either
ineffective workflows (e.g., stepwise testing for the diagnosis of
rare pathogens) or an incomplete diagnostic panel. In recent
years, very high levels of multiplexing have become accessible
using next-generation sequencing (NGS) platforms. NGS
offers a low cost per analyte but comes at the expense of a
high cost per sample, high instrumentation costs, and multiday
workflows: compromises that are unacceptable and have not
been readily adopted in most clinical diagnostic applications.
Affordable mid-density multiplexing with accessible instru-
mentation and minimal workflow requirements is the
compromise between extremes.
Modern qPCR instruments are capable of detecting targets
in multiple color channels, allowing for the multiplexing of 4−
6 analytes per reaction well. While this is certainly an
improvement over single-plex, it is still insufficient in a number
of clinical applications where many different pathogens may
present similar symptoms. In recent months, this has become
particularly important in the context of distinguishing between
SARS-CoV-2 and other respiratory viruses which cause
influenza-like illnesses (ILIs).1 Simultaneously testing for
SARS-CoV-2 as well as most other clinically relevant
respiratory viruses is beyond the traditional multiplexing
capacity of a single well on a qPCR platform. The need for
higher-plex molecular diagnostic panels can be addressed with
more traditional qPCR methods by dividing samples across
multiple wells or using melt temperature separation to
multiplex within a single channel.2 Dividing targets across
multiple wells is effective for assay design, but requiring even a
single extra well per test halves the maximum throughput of
these instruments and increases per-sample reagent costs at a
time when high-volume and low-cost testing is essential. Melt
temperature separation can be conducted in a single well but
requires extra cycling time as well as specialized nontraditional
chemistries to ensure distinct melting temperatures. Addition-
ally highly multiplexed technologies, such as genomic
sequencing, spatial arrays,3 and flow-based target immobiliza-
tion,4 can achieve similar diagnostic outcomes to traditional
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qPCR methods but come at a significantly higher cost and
lower throughput in comparison. For example, systems such as
the BioFire FilmArray spread a sample across an array of wells,
but this requires specialized pouches that both increase cost
and reduce throughput compared to microwell plate-based
tests.
In this paper, we describe a method of using high-definition
PCR (HDPCR) technology from ChromaCode Inc. to detect
up to 20 analytes in a single well using standard qPCR
instrumentation with no workflow modification, allowing for
rapid syndromic testing and significant cost savings. In this
paper, we demonstrate the flexibility of this approach in three
different assays, by showcasing a high-plexity assay design, a
simple off-the-shelf assay design, and a potential application of
this technology to a current public health crisis.
The first assay we present is able to detect 20 targets across 5
color channels in a single well, quadrupling the analytic
capacity of the qPCR instruments used. This assay required
careful design of target sequences to avoid unwanted
secondary amplifications as well as robust multichannel
encodings of target amplification levels to accommodate
hardware variation and increase accuracy. In contrast, the
second assay is constructed directly from off-the-shelf gene
expression qPCR sequences from Integrated DNA Technolo-
gies, Inc. (IDT) and is able to detect 8 targets across 4 color
channels using a simple binary encoding scheme. This
demonstrates that the HDPCR technology can quickly expand
multiplexing capacity by combining existing single-plex Taq-
Man assays without the need for extra sequence design. Finally,
the third assay expands the method to RNA targets by
detecting the SARS-Cov-2 virus along with common strains of
influenza and respiratory syncytial virus in a single well from
clinical samples.
Robust Multichannel Encoding. Previous work demon-
strated the ability to use amplitude modulation to multiplex up
to 12 targets in a single well or 3 targets per channel across 4
different color channels.5 In an amplitude modulation scheme,
each target is assigned a unique endpoint amplitude in each
color channel by modulating the concentration of the TaqMan
probe present. This chemical encoding maps each target to its
expected set of endpoint amplitudes. The previous work used a
simple binary encoding scheme, in which the three targets in
each channel were assigned scaled intensities of 1, 2, and 4.
With this assignment, each possible combination of targets in a
channel corresponds to a unique combined intensity level of 0
through 7 (Figure 1a). In principle, this type of encoding could
be extended to any number of targets per channel; for example,
4 targets in a channel could be encoded at scaled amplitudes of
1, 2, 4, and 8. However, all qPCR instrumentation exhibits
noise, and this noise increases with amplitude. Thus,
consistently distinguishing between amplitudes 14 and 15 is
significantly harder than distinguishing between 6 and 7. In
practice, sophisticated encoding strategies are required to
enable higher orders of multiplexing.
Error-correcting codes have long been utilized for data
transmission and storage. As an example, redundant array of
independent disks (RAID) technology takes advantage of
access to multiple independent storage drives to spread
information across multiple channels.6 In this way, errors in
one storage drive can be detected and often corrected using
uncorrupted data from another drive. We apply an analog
version of this technique to take advantage of the multiple
color channels available on modern qPCR instruments. Rather
than encoding each target in a single color channel, many
targets are given a mixture of probes in multiple channels
(Figure 1b). This robust encoding strategy allows for
improvement over our previously described method by
correcting for noise in one channel using readings from
another, providing a higher overall noise tolerance and thereby
increasing sensitivity and specificity. Such multichannel
encoding schemes must be carefully designed to avoid
degeneracies where multiple different sets of targets amplify
to the same predicted endpoint. Practically, the encoding
scheme must also avoid near-degeneracies, for example, two
sets of targets that amplify to nearly identical predicted
endpoints except for a small difference in one channel. While
these near-degeneracies can still be distinguished in principle,
they lead to higher sensitivity to noise, eliminating the benefit
of multichannel encoding. On top of using a multichannel
encoding, further optimizations are possible depending on the
type of assay being designed. For example, in many clinical
applications for mid-level multiplexing, there is a desire to test
for many possible pathogens, but in practice, it is extremely
rare to find a patient who is simultaneously positive for more
than a few of them. In such cases, it makes sense to design an
encoding scheme that is especially accurate at detecting
combinations of 1, 2, or 3 pathogens. This necessitates trade-
offs that make the encoding comparably less accurate for
combinations of 10 or 15 positive targets, but this is not
relevant if such combinations are never clinically present. We
Figure 1. Amplitude modulation encoding. (a) Single-channel binary encoding. Each target appears in a single channel, and placing individual
targets at binary-spaced levels such as 1, 2, and 4 ensures that all target combinations end at a distinct endpoint. (b) Multichannel robust encoding.
In this example, targets A and B both have probes in channels 1 and 2. The last pane shows a 2D plot of endpoints from all possible target
combinations given the encoding scheme defined in b. The second dimension results in a more spaced-out set of target combination endpoints
compared with binary encoding, which leads to lower risk of misidentification.
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employ such a scheme in the 20-Plex assay presented below,
which spaces out single-target encodings by more than strictly
necessary in order to increase consistency in distinguishing
combinations of up to 4 positive targets. We also make a
special consideration for an internal control (Target T in the
scheme, see Table 1) which is expected to always be present in
successful samples by assigning it a low amplitude and ensuring
that its presence does not lead to potential confusion with
other target combinations.
■ EXPERIMENTAL SECTION
20-Plex Assay. Assay Design. The twenty-target robust
encoding multiplex assay (20-Plex) combines 20 different
TaqMan assays. Each TaqMan assay consists of oligonucleo-
tide primers for amplification and a fluorogenic probe which
may be digested by the 5′ → 3′ exonuclease activity of Taq
polymerase if it hybridized to a complementary amplicon
during amplification, separating a fluorescent molecule from a
quenching molecule.7 The assays were selected from multiplex
panels previously developed for infectious disease detection
applications. For the selection of PCR assays, compatibility of
the 40 primers and 20 unique probe sequences was assessed
with Primer3 software8,9 using the following standard
modeling parameters: ([monovalent cation] = 50 mM,
[divalent cation] = 2.5 mM, and [dNTP] = 0.8 mM,
temperature = 60 °C). This software generates a list of the
least-likely binding heterodimers. From this list, primers with
delta Gibbs free energy (ΔG) of greater than −6 kcal/mole
were selected for the assay. PCR primer sensitivity and
selectivity were confirmed with multiplex wet testing prior to
the multichannel encoding. For the final encoded assay, high-
performance liquid chromatography (HPLC)-purified primers
were obtained from IDT. HPLC-purified TaqMan reporter
probes for each target were ordered from either IDT or
BioSearch Technologies, Inc. Each probe sequence was
obtained with one or more fluorophore/quencher sets
corresponding to channel(s) of detection in the encoding
scheme (Table 1).
Template Preparation. Template DNA samples for each of
the 20 targets were formulated using either gBlock Gene
Fragments (Targets A-O and T) or plasmids (Targets P−S),
which were obtained from IDT. The templates were
formulated in a dilution buffer composed of TE (G-
BioSciences 786−150) with 4 ng per μL of lambda DNA
(New England Biolabs N3011L) to extend low copy number
stability. Concentration of stocks was confirmed using a
Nanodrop Lite spectrophotometer (Thermo Fisher) and
digital droplet PCR on the QX200 Droplet Digital PCR
system (BioRad). First, data from the amplification of
individual targets at 2 × 103 copies per μL were generated
and processed. These data were used for instrument-specific
calibration as described in the Signal Processing section below.
Contrived synthetic samples for this study were formulated
in a diluent containing 4 ng of Lambda DNA per μL plus the
internal control Target T at 1000 copies per reaction. Four
different sample sets were generated:
1. Negative samples.
(a) With internal control.
(b) Diluent with lambda DNA.
2. Single-target sample dilution series (all with the internal
control).
(a) Each target at 105, 104, 103, and 102 copies per reaction.
3. Dual-target samples at 4 different dilutions (all with
internal control).
(a) Symmetric: both targets at 104 copies per reaction.
(b) Symmetric: both targets at 102 copies per reaction.
(c) Asymmetric: Target X at 104 and Target Y at 102 copies
per reaction.
(d) Asymmetric: Target X at 102 and Target Y at 104 copies
per reaction.
4. Triple-target plus internal control.
(a) Symmetric: all targets at 104 copies per reaction.
5. Quadruple-target plus internal control.
(a) Symmetric: all targets at 104 copies per reaction.
Discordant Analysis. For discordant samples with suspected
Target S contamination, single-plex analysis was performed on
diluted amplicon. Post-PCR discordant samples were diluted
10−6, 10−7, 10−8, and 10−9 in TE. The diluted amplicon was
tested using a single-plex assay with two primers and 1 probe
specific for Target S along with a serial dilution of Target S
standard at 105, 104, 103, and 102 copies per reaction. The
discordant samples and diluted standard were run with the
same parameters as the multiplex assay on the Applied
Biosystems QuantStudio 5 Real-Time PCR system. Six
discordant samples showing amplification in the single-plex
assay and 3.3 Ct spacing between 10-fold dilutions were
determined to contain trace amounts of Target S, and these
samples were subsequently excluded from analysis.
8-Plex with IDT Predesigned Assays. Assay Design.
The 8-Plex assay combined 8 different off-the-shelf TaqMan
assays from IDT directly ordered from their product page for
predesigned qPCR assays (https://www.idtdna.com/site/
order/qpcr/predesignedassay). The assays were selected for
human transcriptome targets which have been demonstrated to
be highly correlated to sepsis10 (Table S1), and the oligo
sequences of the final assay are listed in Table S2.
A concentrated multiplex primer and TaqMan probe mix
was formulated so two targets could be detected in each of the
Table 1. 20-Plex Targets and Engineered Intensity Levels by
the Channel
name x1-m1a x3-m3 x4-m4 x5-m5 x6-m6
target A 3 0 0 0 0
target B 4 3 0 0 0
target C 7 0 0 0 0
target D 0 1 6 0 0
target E 0 2 5 0 0
target F 0 4 3 0 0
target G 0 7 0 0 0
target H 0 0 1 6 0
target I 0 0 2 5 0
target J 0 0 4 3 0
target K 0 0 7 0 0
target L 0 0 0 1 6
target M 0 0 0 2 5
target N 0 0 0 4 3
target O 0 0 0 7 0
target P 6 0 0 0 1
target Q 5 0 0 0 2
target R 3 0 0 0 4
target S 0 0 0 0 7
target T 1 1 0 0 0
ax1-m1 is the instrument notation for excitation filter 1 and emission
filter 1.
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four excitation/emission filter sets on the qPCR instrument.
The targets and their respective intensity levels for each filter
set are listed in Table 2. In order to ensure the differential
intensity levels between targets in the same channel, the
intensity level 2 probe was included at twice the concentration
of the intensity level 1 probe.
Template Preparation. Templates were formulated using
gBlock Gene Fragments obtained from IDT. Two types of
samples were prepared.
1. Single-target sample dilution series.
(a) Each target at 105, 104, 103, 102, 101, and 10 copies per
reaction.
2. Dual-target samples at 3 different dilutions.
(a) Symmetric: both targets at 104 copies per reaction.
(b) Asymmetric: Target X at 104 and target Y at 102 copies
per reaction.
(c) Asymmetric: Target Y at 104 and Target X at 102 copies
per reaction.
All samples were prepared at the same time. All possible
single- and dual-target combinations were generated.
Discordant Analysis. In initial testing, 10 samples showed
unexpected signals that led to suspicion of contamination. The
phenotype of these samples was consistently a correct call for
the expected targets and an additional amplification curve with
a very late cycle threshold. To test for stock contamination, 12
replicates of each template stock were run at 107 copies per
reaction. Results showed low levels of contamination in
multiple stocks, with at least 11/12 replicates showing the
unexpected presence of ACTB or ENTPD1. These contami-
nated stocks were present in the 10 samples with suspected
contamination, so all 10 were excluded from analysis. This type
of contamination is common among high concentration
synthetic templates which are manufactured together.
9-Plex Expanded SARS-CoV-2 Prototype Assay. Assay
Design. The 9-Plex expanded SARS-CoV-2 prototype assay
was developed to detect SARS-CoV-2 as well as subtypes of
common respiratory targets influenza A/B and Respiratory
Syncytial Virus A/B. The design started with the published
CDC SARS-CoV-2 assay and influenza B assay.11,12 To
improve sensitivity and specificity, new assays for influenza A
Universal (PB1 Gene), influenza A H1 and H3 subtyping, and
Respiratory Syncytial Virus A/B were designed using a custom
automated design pipeline based upon RUCS: Rapid
identification of PCR primers for unique core sequences.13
A multiplex primer mix at a 10× concentration was made by
adding all primers into a single vessel which when diluted
yielded a final 1× concentration. A multiplex probe mix was
made by adding in each probe at a specific concentration to
achieve the ratios specified in Table 3. The primer and probe
mixes were combined to create a 5× oligo mix.
Samples. Remnant clinical nasopharyngeal swab specimens
collected in viral transport media prior to 2019 were
characterized as being positive for influenza A H1 or H3,
influenza B, un-subtyped RSV, or negative using either the
Cepheid Xpert Flu assay and The BioFire FilmArray
Respiratory (RP) Panel. SARS-CoV-2 samples were contrived
by spiking in by Asuragen [Armored RNA Quant SARS-CoV-2
(PN: 52030)] into a nasopharyngeal sample matrix previously
screened for SARS-CoV-2 using the ChromaCode HDPCR
SARS-CoV-2 assay and shown to be negative. Samples were
spiked in at various concentrations between 32,000 and 2000
copies/mL. Clinical and contrived samples were extracted on
the Roche MagNA Pure 24. Samples were extracted using the
MagNA Pure 24 Total NA Isolation Kit (Roche
07658036001) Pathogen 200 2.0 protocol. Sample input
used was 200 μL. Samples were eluted in 50 μL.
Discordant Analysis. One clinical sample was called
influenza A H3 subtype by the expanded SARS-CoV-2
prototype assay, which was discrepant with the reported
influenza A H1 2009 subtype on the BioFire FilmArray
Respiratory Panel comparator assay during initial testing. To
confirm this result, three single-plex qPCR assays designed to
detect influenza A, influenza A H1 2009 subtype, and influenza
A H3 subtype were performed. These tests detected influenza
A and influenza A H3 subtype but not influenza A H1 2009
subtype, in agreement with the SARS-CoV-2 prototype assay
call. This sample was excluded from subsequent analysis.
qPCR Testing Parameters. The qPCR’s for all assays were
set up on Applied Biosystems MicroAmp Fast Optical 96-Well
Reaction Plates 0.1 mL (ABI 4346906) using 10 μL of 2×
Enzyme Mix 03 (ChromaCode 0381) and 5 μL of the sample.
For the 20-Plex and IDT assays, 5 μL of 4× oligo mix was
added, while for the SARS-CoV-2 prototype assay, 4 μL of 5×
oligo mix and 1 μL of reverse transcriptase (ChromaCode
0081) were added. Upon completion of loading the well, the
plate was sealed with MicroAmp Optical seals (ABI 4311971)
and then spun down.
Thermal cycling and detection was performed on the
Applied Biosystems QuantStudio 5 Real-Time PCR system
(QS5) with a 96-well 0.1 mL block (Thermo Fisher Scientific
Catalog #A28138). For the 20-Plex and IDT assays, the
thermal cycling parameters were programmed to include an
initial denaturing hold at 95 °C for 60 s followed by 55 cycles
of a 95 °C 10 s denaturing step plus a 60 °C for 60 s combined
annealing and extension step. Fluorescence data were collected
for all paired filter sets (x1-m1 through x6-m6) during the 60
Table 2. IDT Predesigned Targets and Engineered Intensity
Levels by the Channel
name x1-m1 x2-m2 x4-m4 x5-m5
AGTRAP 2 0 0 0
ACTB 1 0 0 0
MMP 0 2 0 0
IRAK 0 1 0 0
ENTPD 0 0 2 0
TKL1 0 0 1 0
ALOX 0 0 0 2
FCER1B 0 0 0 1
Table 3. Expanded SARS-CoV-2 Prototype Targets and
Engineered Intensity Levels by the Channel
name x1-m1 x2-m2 x4-m4 x5-m5
influenza A (universal) 1 0 0 0
influenza A H1 2 0 0 0
influenza A H3 4 0 0 0
SARS-CoV-2 N1 0 1 0 0
SARS-CoV-2 N2 0 4 0 0
RSV A 0 0 1 0
RSV B 0 0 1 0
influenza B 0 0 0 3
hRNase P 0 0 0 1
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°C step. The total run time was 75 min and 15 s. The
expanded SARS-CoV-2 prototype assay thermal cycling
parameters were almost equivalent, with the addition of a
reverse transcription hold at 50 °C for 15 min at the beginning
of PCR, a 3 s denaturing step, and an annealing/extension
stage at 55 °C. In the QuantStudio Design & Analysis Desktop
Software version 1.5.1, the Sample Setup, Multicomponent
Data, and Raw Data tabs were exported in Microsoft Excel 97-
2004 Workbook(.xls) format and were analyzed with the signal
processing and call algorithms described below using the
Python Programming language (Python Software Foundation,
https://www.python.org/).
■ ANALYSIS METHODS
Signal Processing. Before interpreting the encoded
signals, a set of proprietary signal processing steps are applied
to correct for inherent noise and variability in the PCR and
instrumentation. These include compensations for spectral
bleed-through and variation in sensitivity between wells to
correct for instrument-to-instrument variability as well as
reaction-to-reaction variability. The progression and culmina-
tion of all of these steps are shown in Figure 2.
In the first of the instrument-independent steps, each time
series is normalized relative to its baseline intensity prior to
amplification. The baseline intensity is directly correlated to
the amount of the probe mixture in the well, so normalizing by
this value corrects for pipetting error as well as optical gain
differences across the instrument. The final steps of smoothing
Figure 2. Stepwise signal processing. These graphs show 96 replicates of Target O at 10,000 copies per reaction as detected by filter set x5-m5
(red) and filter set x6-m6 (blue): (a) Raw data directly from instrument export, (b) data after spectral bleed-through correction, (c) data after
signal normalization, and (d) data after geographic correction and smoothing.
Figure 3. Target identification method. A 2-target, 2-channel example was used to illustrate the target identification method. In the first two panels,
the dotted lines represent expected exemplars of data from each individual target as well as their combination, and the black line represents data
which were observed from an actual sample. In the third panel, the endpoints of each expected combination plotted in 2D distances are drawn from
the sample to each expected location. Since the sample is the closest to the red point, it would be called as only having target 1.
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and baseline offsetting primarily serve to increase ease of data
visualization.
Data Analysis. The first step in data analysis is determining
the expected endpoint intensity values of every possible
combination of targets to create a decoding table. For the 20-
Plex assay, this maps each one of the 1,048,576 (220) possible
target combinations to a predicted location in the five-
dimensional space created by the 5 color channels. During
initial testing, 8 replicates of each target in single presence
along with 8 no-template (NTC) replicates were run for each
assay. Taking the median endpoint intensity among each set of
single-presence replicates and subtracting the intensity of the
NTC replicates allowed for precise determination of how
much intensity each target contributed in each channel. A
combination of multiple targets would then be expected to
have a final intensity of the sum of the individual intensities of
each of these targets plus the NTC intensity. The target
intensities for all assays (Tables 1−3) were chosen so that no
two target combinations occupied the same predicted location.
Once these expected intensities are determined, we can use
them to identify the combination of targets present in any
given sample. The distance from a sample to each possible
target combination is calculated by taking difference between
the natural logs of the sample’s and each target combination’s
intensities in each channel. The logarithmic component takes
into account the fact that variance in intensity increases with
increasing signal, so the difference between intensities of 1 and
2 is more significant than the difference between intensities of
9 and 10. The unknown sample identity is determined by
finding the closest combination of predicted endpoints to the
observed sample endpoints (Figure 3).
■ RESULTS AND DISCUSSION
Results. 20-Plex Assay. The testing of the assay consisted
of a total of 1080 samples across 12 plates (6 wells on each
plate were dedicated to controls which were not included in
analysis or final results). Of these samples, 60 contained no
target DNA, 164 contained only an internal control (IC), 456
contained a single positive target plus the IC, 350 contained
two positive targets plus the internal control, 35 contained
three positive targets plus the IC, and 15 contained four
positive targets plus the IC. The single-target samples covered
every target in concentrations from 100 to 100,000 copies per
reaction in multiples of 10, and the dual-target samples covered
16 different combinations, each in concentration combinations
of 10k/10k, 10k/100, 100/10k, and 100/100 copies per
reaction. The three- and four-target samples covered seven and
three target combinations, respectively, with all targets at a
concentration of 10k copies per reaction. Due to the large
amount of combinations possible, not all combinations were
tested for this group. Upon analysis of these samples six
suspected instances of Target S contamination were identified,
which were subsequently confirmed by reanalyzing the samples
in single-plex. A summary of the accuracy across all of these
samples, after excluding these contaminated samples, is shown
in Table 4. Each sample is listed as “correct” only if we
correctly identified the exact set of targets present. An overall
well accuracy of 98.8% was achieved.
Sensitivity and specificity statistics for each target are shown
in Table 5. We achieve greater than 97% sensitivity and 99%
specificity for every target except for Target I, which had a
lower sensitivity of 93.3%.
8-Plex with IDT Predesigned Assays. We tested this
assay on a total of 418 wells across 5 plates. Of these, 6
contained no target DNA, 160 contained a single positive
target, and 252 contained two positive targets (covering all 28
possible 2-target combinations). Because this assay was simpler
than the 20-plex, sufficient accuracy was obtained by skipping
instrument-specific calibration steps and instead using
corrected multicomponent data output directly by the
instrument software. After further analysis, it was determined
that 10 samples showed strong evidence of contamination and
were discarded. The analysis results among the remaining 402
samples are shown in Table 6. We achieve an overall well
accuracy of 98.3%. To help visualize the data, curves from all
single-target dilutions are shown in Figure 4.
Sensitivity and specificity were calculated for each individual
target. Every target had a sensitivity of at least 96% and a
specificity of at least 99% with an overall sensitivity of 98.9%
(Table 7).
9-Plex Expanded SARS-CoV-2 Prototype Assay. A total
of 71 clinical samples and 4 no-template control (NTC)
samples were tested on a single plate, including 10 which were
contrived to be positive for SARS-CoV-2 using Armored RNA
Quant SARS-CoV-2 Control, an in vitro-transcribed RNA
encapsulated in a protective protein coat (Asuragen PN:
52030). As with the IDT assay, instrument-specific calibration
was removed from the signal processing. SARS-CoV-2-positive
samples were considered to be called correctly if at least one of
the N1 or N2 targets was identified. Samples positive for
influenza A H1 or H3 were considered to be called correctly if
the subtype target was identified correctly with or without the
universal influenza A target (i.e., influenza A H3 + influenza A
universal or influenza A H3 alone are considered to both
correctly identify an influenza A H3 sample). Finally, samples
positive for any form of RSV were considered to be called
correctly if at least one of the RSVA or RSVB targets was
identified. With these criteria, all 75 of the samples were called
correctly (Table 8). The internal hRNase P control also
amplified successfully in all 71 non-NTC samples.
For the 26 influenza A samples, there were 5 instances (4 for
H1 and 1 for H3) in which the proper subtype target was
detected but the universal influenza A target was not. For the
10 SARS-CoV-2 samples, there were 3 instances where the N2
gene target was detected but the N1 gene target was not. For
the RSV samples, it was impossible to subtype with this assay
design because RSVA and RSVB were both placed at the same
intensity. We identified these all as correct calls based on our
criteria, but this may not match standards applied in clinical
testing. If we instead evaluate each target as an individual assay,
we attain sensitivities of 80.8 and 70% for the influenza A
Universal and the SARS-CoV-2 N1 Gene, leading to overall
sensitivity of 92.1%.
Table 4. 20-Plex Assay Results by Positive Target Count
target count correct calls incorrect calls excluded % accuracy
0 60 0 0 100%
0 + IC 163 0 1 100%
1 + IC 452 1 3 99.8%
2 + IC 338 11 1 96.8%
3 + IC 34 1 0 97.1%
4 + IC 14 0 1 100%
total 1061 13 6 98.8%
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■ DISCUSSION
This study demonstrates that augmenting HDPCR technology
with novel signal processing and robust multichannel encoding
enables substantial increases in multiplexing capacity with
standard TaqMan reagents and multiwell qPCR instruments.
As a proof of principle, twenty different targets for viral and
bacterial pathogens were combined in a one-well assay,
increasing the total interrogable targets per channel four-fold.
Analysis of a test panel of >1000 contrived samples
demonstrates that the method has very high overall sensitivity
>99% and specificity = 99.9% with an overall well accuracy of
>98.5%.
This novel technique makes mid-density multiplexing a
possibility with off-the-shelf qPCR instrumentation and can be
applied to any nucleic acid detection panel, including common
diagnostic panels such as respiratory, blood culture identi-
fication, gastrointestinal, or antimicrobial resistance. The use of
off-the-shelf TaqMan reagents and common instrumentation
with a significant existing install base often removes the need
for any new capital expenditures and allows for significant cost
savings and increased throughput compared to other single-
plex and multiplexing technologies.
The signal processing and target identification algorithms
required no on-plate calibrator wells, allowing the entire plate
to be utilized for samples and quality controls. The individual
target calibration proved to be very robust as the instrument
was transported mid-study and no further additional
calibration was required after this event. This makes the
robust multichannel encoding technique instrument-agnostic,
Table 5. 20-Plex Assay Sensitivity and Specificity Results by the Target
target true positives true negatives false positives false negatives sensitivity specificity
A 64 1011 5 0 100% 99.5%
B 119 961 0 0 100% 100%
C 74 1004 2 0 100% 99.8%
D 49 1031 0 0 100% 100%
E 79 1001 0 0 100% 100%
F 74 1006 0 0 100% 100%
G 94 980 6 0 100% 99.4%
H 94 986 0 0 100% 100%
I 83 991 0 6 93.3% 100%
J 54 1026 0 0 100% 100%
K 84 996 0 0 100% 100%
L 49 1031 0 0 100% 100%
M 49 1031 0 0 100% 100%
N 44 1036 0 0 100% 100%
O 69 1011 0 0 100% 100%
P 68 1011 0 1 98.5% 100%
Q 63 1015 1 1 98.4% 99.9%
R 43 1036 0 1 97.7% 100%
S 59 1015 0 0 100% 100%
T 1014 60 0 0 100% 100%
totala 1308 19,175 14 9 99.3% 99.9%
aTotal excludes internal control Target T.
Table 6. 8-Plex Assay Results by Positive Target Count
target count correct calls incorrect calls excluded % accuracy
0 6 0 0 100%
1 156 0 4 100%
2 239 7 6 97.1%
total 401 7 10 98.3%
Figure 4. IDT predesigned assay single-target dilution curves. Ten-fold serial dilution of each target in the IDT off-the-shelf assay diluted from
100,000 to 10 copies per reaction.
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enabling use in 96- and 384-well plates for high-throughput
applications or single-well plates for near-patient instrumenta-
tion.
Low-level template contaminations observed in the 20-Plex
and 8-Plex assays were traced back to the template panels used
to assess the assays and not spurious signal generated from
oligo dimers. These panels were constructed with synthetic
double-stranded DNA template which is manufactured and
processed at greater than 1012 copies per sample tube. These
high-concentration templates were all manufactured and
shipped in a single order, increasing chances for contami-
nation. Similar contamination would not be expected when
testing clinical samples since they would not contain high-
concentration synthetic templates.
The assays described herein are only prototypes and not yet
suitable for clinical deployment. In future clinical translational
studies, these prototype assays would have to be further
analyzed for limit of detection at lower target concentrations
and with a larger variety of clinical samples to further evaluate
clinical performance. An additional consideration of the
HDPCR technique is that it makes quantitation more difficult
in some circumstances. If only one target is present in a sample
it is still possible to quantitate with normal methods by
comparing an amplification cycle threshold to standards
(although we do not demonstrate this here). However, if
multiple targets are present, which both amplify in the same
channel, these traditional methods of cycle threshold will not
apply. It is still possible to consider adding an upper bound on
a target concentration by looking at the threshold of the first
amplification signature in a channel, and more precise analysis
of “double-bump” features in channels with multiple
amplifications could allow for rough quantitation beyond this
upper limit, but this is beyond the scope of this work. The
necessity for quantitation on mid-plexed infectious disease-
based panels is disputable, as many panels currently on the
market simply detect the presence or absence of pathogens,
which is sufficient to inform physicians. There has been some
demonstration for clinical utility of quantitation of the SARS-
CoV-2 virus in the literature,14 but for many applications,
simple detection of the presence is sufficient.
■ CONCLUSIONS
The 20-Plex assay demonstrates the full potential of HDPCR
technology when the sequences in use are designed to avoid
cross-reactivity and a simple, one-time instrument calibration is
performed prior to use. However, these steps may not be
possible, or even necessary, in every situation. The off-the-shelf
assay used sequences ordered directly from the existing IDT
predesigned assay catalogue and utilized a simplified strategy
which did not require extra sequence design, instrument
calibration, or carefully designed multichannel encodings.
Without these extra steps, HDPCR technology was still able
to reliably detect 8 targets per well across 4 color channels,
doubling the normal multiplexing capacity of the qPCR
instrument. This simplified assay design strategy was also
applied to the urgent task of detecting SARS-CoV-2 along with
other common ILIs with which it may be confused based on
symptoms alone. The expanded SARS-CoV-2 prototype assay
was designed to detect 8 targets plus an internal control in a
single well and achieved 92% overall sensitivity on the 71
clinical samples tested with 100% accuracy on viral
identification. As of November 2020, the United States is
currently running over 1 million SARS-CoV-2 tests per day,15
and this volume will need to continue well into 2021 to
contain the pandemic until widespread vaccination is
achieved.16 This unprecedented need for widespread testing
is already putting significant strain on existing diagnostic
capacity. The use of HDPCR technology could allow the
diagnostic industry to expand the usage of their current qPCR
platforms to test for SARS-CoV-2 and other respiratory viruses
all in a single well without additional investments in
infrastructure or complications in workflow.
■ ASSOCIATED CONTENT
*sı Supporting Information
The Supporting Information is available free of charge at
https://pubs.acs.org/doi/10.1021/acs.analchem.0c04626.
All IDT assay IDs and raw sequences used in the 8-Plex
assay and all processed PCR curves used to make target
calls available for download (ZIP)
Table 7. 8-Plex Assay Sensitivity and Specificity Results by the Target
target true positives true negatives false positives false negatives sensitivity specificity
ACTB 75 323 2 2 97.4% 99.4%
AGTRAP 78 321 0 3 96.3% 100%
IRAK3 81 320 1 0 100% 99.7%
MMP9 83 319 0 0 100% 100%
ENTPD1 80 322 0 0 100% 100%
TKTL1 81 321 0 0 100% 100%
ALOX5 81 319 0 2 97.6% 100%
FCER1b 81 318 3 0 100% 99.1%
total 640 2563 6 7 98.9% 99.8%
Table 8. Expanded SARS-CoV-2 Prototype Assay Results by
the Target
sensitivity specificity
influenza A universalb 21 49 0 5 80.8% 100%
influenza A H1 16 59 0 0 100% 100%
influenza A H3 10 65 0 0 100% 100%
influenza B 20 55 0 0 100% 100%
RSV 9 66 0 0 100% 100%
SARS-CoV-2 N1 geneb 7 66 0 3 70% 100%
SARS-CoV-2 N2 geneb 10 66 0 0 100% 100%
hRNAse P 71 4 0 0 100% 100%
totala 93 426 0 8 92.1% 100%
aTotal excludes internal control target hRNAse P. bSubtyping target
not considered necessary for correct viral identification if other
subtyping targets are present.
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